While GLP-1 receptor agonist has been proven to provide cardiorenovascular protection, studies conducted on animals and in vitro suggest that there are possible renoprotective actions of GIP in humans, because GIP influences several mechanisms that take part in diabetic nephropathy development and progression by reducing proinflammatory and profibrotic states factors. This evidence concerns the gene GIP and diabetic kidney disease.